AstraZeneca Results Presentation Deck
Calquence and Enhertu
Launches continued ahead
Calquence: 150% growth to $0.5bn
$m Approvals: 66 (CLL¹) and 32 countries (MCL²)³
350
300
250
200
150
100
50
0
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
●
●
●
Global $490m; US $445m
US CLL
Earlier use; share
of new patients:
Front line c.45% of BTKI4
class and >15% overall5
Relapsed/refractory c.45%
of BTKi class; c.20% overall5
Global CLL
DE, UK largest contributors
US Europe EROW EM
Total revenue at actual exchange rates. 1. Chronic lymphocytic leukaemia 2. Mantle cell lymphoma (R/R) 3. Reimbursement in 15 and
10 countries, respectively 4. Bruton tyrosine kinase inhibitor 5. IQVIA market research.
13
$m
50
25
Q1 2020
Enhertu
Approvals: US, EU, JP (mBCº); US, JP (mGC7)
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
●
Global $89m; US $75m
$161m total US in-market
sales by Daiichi Sankyo
France early access and
early launch sales
elsewhere, incl. UK
00-406-41
ENHERTU
-rastrual dedica
nection
B
100 mg per vial
nu insion Onl
and Dute pro to
Cytotec Age
NDC 65597-406-01
Rx only
ENHERTUⓇ
(fam-trastuzumab deruxtecan-nxki)
For Injection
100 mg per vial
For Intravenous Infusion Only
Dispense the enclosed Medication Guide to each patient.
Reconstitute and Dilute prior to administration
Single-Dose Vial
Discard Unused Portion
CAUTION: Cytotoxic Agent
KEEP REFRIGERATED
1 vial
Daiichi-Sankyo AstraZeneca
US Europe EM
Total revenue at actual exchange rates, including $4m of sales. 6. Metastatic breast cancer (3L, HER2+) 7. Metastatic gastric
cancer (3L/2L+, HER2+).
3View entire presentation